SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Scott who wrote (1426)1/15/1998 8:56:00 PM
From: Pseudo Biologist   of 1762
 
Scott, thanks much, this is great information, and the examples are helpful.

Given the buzz in the popular press and other places about the potential tightness under managed care, one cannot help but wonder how terms like "relatively mainstream" and "reasonably related" may be interpreted by those who approve payment, especially for a brand-new drug. Given Rituxan's reasonable cost (compared to rounds of chemotherapy) and fairly mild side effect profile, one would hope reimbursement would be a slam dunk for many off-label uses. However, I rather don't assume those things, and ask around instead. I brought up the issue in the context of your post, because it "sounded" (how do typed words sound?) as if you could have an interesting and informed take on the matter.

Thanks again,

PB
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News